<DOC>
	<DOC>NCT02333149</DOC>
	<brief_summary>This study is a multi-center, randomized, triple-blind, placebo-controlled parallel-group trial, in which each participant is offered an N-of-1 trial. The purpose of this study is to assess the efficacy and safety of melatonin (3 mg or 6 mg) compared with placebo for initial insomnia in children with attention-deficit disorder.</brief_summary>
	<brief_title>Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Schoolaged children and adolescents between the ages of 6 to 17 years Confirmed diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) Comorbid psychiatric/neurological diagnoses that may affect sleep Comorbid seizure disorder Comorbid sleep disorder Concurrent use of immunosuppressive drugs, blood pressure drugs, selective serotonin reuptake inhibitors or anticoagulant drugs; Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Melatonin</keyword>
</DOC>